InMed Pharmaceuticals Inc. (OTCMKTS:IMLFF – Get Free Report) shares fell 9.2% during mid-day trading on Friday . The company traded as low as $0.26 and last traded at $0.27. 471,246 shares traded hands during mid-day trading, an increase of 4,045% from the average session volume of 11,369 shares. The stock had previously closed at $0.29.
InMed Pharmaceuticals Price Performance
The stock’s 50-day moving average is $0.27 and its 200-day moving average is $0.26.
About InMed Pharmaceuticals
InMed Pharmaceuticals Inc, a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain.
Recommended Stories
- Five stocks we like better than InMed Pharmaceuticals
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Energy Vault Soars 100%: CEO Shares Why in MarketBeat Exclusive
- What is a SEC Filing?
- Meta’s Q3 Earnings Beat—Is This Dip a Golden Entry Opportunity?
- What is a Dividend King?
- Top Nuclear Stocks Thriving on Soaring Energy Demand
Receive News & Ratings for InMed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
